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Background/Introduction
Altered substrate metabolism plays an important role in
pathophysiology of heart failure (HF). Optimization of
myocardial energy metabolism with metabolic modula-
tors like trimetazidine (TMZ) allows more efficacious
energy production.
Aims/Objectives
Although TMZ has been studied extensively in patients
with ischemic HF, more data are needed on its role in
dilated cardiomyopathy (DCM).
Method
100 patients of DCM (mean age 47.7 yrs, NYHA class
2.17, LVEF 27.3%) were randomized to TMZ (20 mg tid, n
= 50) vs conventional therapy (n = 50). Functional status,
BNP & echocardiographic parameters were assessed at
3-6 months.
Results
Baseline characteristics were comparable among the two
groups. At three months, patients on TMZ had signifi-
cant improvement in mean NYHA class (2.25 vs 1.85,
p = .001), 6 min walk test (349.7vs 402 m, p = 0.001),
LVD-36 score (25.5 vs 21, p = .001) and fall in BNP
(744.7 vs 248.3 pg/ml, p = .001). This was accompanied
by significant improvement in indexed LV end-systolic
(LVESV, 87.1 ± 27.5 vs 78.5 ± 24.9 ml/m2, p = 0.0001)
and LV end-diastolic volumes (LVEDV, 117.6 ± 29.3 vs
110.9 ± 27.4 ml/m2, p = 0.0001) and LVEF (27vs30.9%,
p = .0001) along with reduction in LV wall stress (90.2 ±
18.9 vs 71.1 ± 13.2 dyn/cm2, p = 0.0001). Other echocar-
diographic parameters also improved after three 3 month
of TMZ (E/A ratio, E/A VTI, Myocardial performance
index) and TDI parameters (E/e’septal, and E/e’ lateral).
Patients not on TMZ had no significant change in
NYHA Class, LVD-36 scores, LV volumes or LVEF at
3 months although BNP levels & LV wall stress reduced,
albeit to a lesser extent than TMZ. Patients on TMZ had
further improvement in NYHA Class, 6 min walk test,
BNP levels & all echocardiographic parameters at
6 months.
Discussion/Conclusion
Metabolic modulators like trimetazidine have a potential
role to play in altering LV remodelling and improving
LV function in DCM. In this study, benefit was noted
by 3 months with further improvement at 6 months.
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